AKT-1/2 inhibitor BAY1125976

Drug Overview

Targeted Therapy / “Smart Drug”

AKT-1/2 inhibitor BAY1125976 is an advanced, experimental cancer medicine. It belongs to a modern family of treatments known as “Targeted Therapies” or “Smart Drugs.” Unlike traditional chemotherapy that attacks all fast-growing cells in the body (which causes side effects like hair loss), smart drugs are designed to find and block specific broken parts inside cancer cells.

Currently, BAY1125976 is an investigational drug. This means it is not available at your local pharmacy. It is actively being studied in early clinical trials at major research hospitals. Doctors are testing it to see how well it fights advanced solid tumors, especially breast and prostate cancers that have stopped responding to standard treatments.

• Generic Name: AKT-1/2 inhibitor BAY1125976 (often referred to as BAY 1125976)
• US Brand Names: None (Currently an investigational drug)
• Drug Class: AKT Kinase Inhibitor / Targeted Therapy / Small Molecule Inhibitor
• Route of Administration: Oral (Tablet or Capsule)
• FDA Approval Status: Not FDA Approved. It is actively being evaluated in Phase I and Phase II clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how BAY1125976 works, we must look inside the cells at the molecular level.

Inside our cells, there is a communication network called the PI3K/AKT/mTOR signaling pathway. You can think of this pathway as a set of traffic lights that tells the cell when to grow, divide, and survive. In many types of cancer, these traffic lights are broken and permanently stuck on “green.” This causes the cancer cells to multiply out of control and refuse to die when they naturally should.

A key protein keeping this green light on is called AKT (specifically the AKT1 and AKT2 versions).

BAY1125976 is an “allosteric inhibitor” of AKT. This means it works like a specialized lock and key. Instead of just blocking the active part of the AKT protein, the drug attaches to a specific pocket on the side of the protein. When the drug binds there, it physically changes the shape of the AKT protein, locking it in an “off” position. Because the protein is locked, it cannot move to the outer edge of the cell (the cell membrane) where it normally gets activated.

By turning off AKT1 and AKT2, the drug successfully turns the traffic light to red. Without the constant signal to grow, the cancer cells stop dividing and eventually trigger their own natural death (a process known in science as apoptosis).

FDA Approved Clinical Indications

Important Note: Because BAY1125976 is an experimental medication, it does not currently have official FDA approvals for general public use. However, it is being actively tested in clinical trials for the following investigational oncological uses:

• Treatment of advanced solid tumors (cancers of the organs or tissues).
• Treatment of metastatic breast cancer that carries specific genetic mutations (like PIK3CA or AKT1 mutations).
• Treatment of advanced prostate cancer and certain gynecological cancers.

Non-oncological uses:

• None. This drug is strictly being studied for cancer treatment.

Dosage and Administration Protocols

Because BAY1125976 is an investigational drug, the exact dosage is decided by strict clinical trial rules. Doctors are still studying the best and safest dose. The information below reflects the general dosing protocols used in early Phase I clinical studies.

Dose Adjustments

• Renal/Hepatic Insufficiency (Kidney/Liver Issues): Standard dose adjustments for people with kidney or liver disease are not fully established yet. In clinical trials, doctors closely check a patient’s liver and kidneys through weekly blood tests. If there are signs of organ stress, the trial doctor may lower the daily dose or pause the treatment temporarily to let the body recover.

Clinical Efficacy and Research Results

Recent clinical research between 2020 and 2025 has focused on establishing the safety limits of the drug and seeing how it works in humans.

• Stable Disease: In early Phase I trials, while massive tumor shrinkage was rare when the drug was used all by itself, a notable portion of patients (often up to 20% to 30% with specific mutations) achieved “stable disease.” This means their cancer stopped growing and spreading for a period of time.
• Biomarker Success: Research shows that the drug works best in patients whose tumors have specific genetic mutations in the AKT or PIK3CA genes. Testing for these markers helps doctors predict who will benefit most.
• Combination Strategies: Because cancers can eventually find a way around a single drug, ongoing research is testing BAY1125976 combined with other therapies (like hormone-blocking drugs for breast cancer) to improve long-term survival rates and disease progression delays.

Safety Profile and Side Effects

Like all targeted therapies that block the AKT pathway, BAY1125976 can affect healthy cells that also rely on this pathway for normal functions, particularly for processing sugar.

Black Box Warning

There is no FDA Black Box Warning for BAY1125976, as it is still in the investigational phase.

Common Side Effects (Occur in >10% of patients)

• Hyperglycemia (High Blood Sugar): The AKT pathway normally helps the body process insulin. Blocking it causes blood sugar levels to rise, which is the most common side effect.
• Gastrointestinal Issues: Nausea, mild vomiting, and diarrhea.
• Fatigue: Feeling unusually tired, weak, or lacking energy.
• Skin Rash: Red, itchy breakouts on the skin.
• Liver Enzyme Elevation: Mild changes in liver blood tests, showing the liver is working hard to process the drug.

Serious Adverse Events (Occur rarely)

• Severe Hyperglycemia: Dangerously high blood sugar that may require emergency insulin treatment.
• Severe Liver Toxicity: High levels of inflammation in the liver that requires stopping the drug.

Side Effect Management Strategies

• For High Blood Sugar: Doctors will check your blood sugar very frequently. Patients often need to follow a low-sugar diet and may need to start taking diabetes medications (like metformin) while on the trial.
• For Diarrhea and Nausea: Keep over-the-counter anti-diarrhea and anti-nausea medicines on hand. Drink plenty of water to avoid dehydration.
• For Skin Rashes: Use gentle, unscented lotions and avoid long periods in the hot sun.

Research Areas

BAY1125976 is a major focus in the research area of overcoming drug resistance. Many cancers eventually become resistant to standard chemotherapies or hormone therapies by activating their PI3K/AKT pathways as an escape route. Scientists are actively testing this drug to block that escape route. There is currently no significant research linking this specific drug to stem cell therapies or regenerative medicine, as its primary role is to stop cancer cell growth, not to regrow tissue.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

• Blood Sugar Testing: A fasting blood glucose test and an HbA1c test must be done to check for hidden diabetes before starting the drug.
• Genetic Profiling: The tumor must be biopsied and tested to see if it carries the specific AKT or PIK3CA mutations that the drug targets.
• Liver and Kidney Panels: Blood tests to ensure the organs are healthy enough for an experimental drug.

Precautions During Treatment

• Dietary Monitoring: Because this drug can quickly raise blood sugar, patients must be very careful about eating sugary foods, sodas, or simple carbohydrates.

Do’s and Don’ts

• DO ask your oncologist if you qualify for a clinical trial testing an AKT inhibitor if you have advanced solid tumors.
• DO check your blood sugar at home every day if your trial doctor gives you a glucose monitor.
• DO swallow the pills whole with a full glass of water.
• DON’T start any new vitamins, herbal supplements, or other medications without telling your clinical trial team, as they might cause dangerous interactions.
• DON’T ignore signs of high blood sugar, such as feeling extremely thirsty, needing to urinate very often, or having blurred vision. Contact your trial team immediately if this happens.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. It should not be used to diagnose, treat, cure, or prevent any disease or health condition. Always consult with a qualified healthcare professional or your treating oncologist regarding specific medical concerns, clinical trial eligibility, treatment options, or before starting, stopping, or altering any medication regimen. Every patient’s medical situation is unique, and therapies should be customized by a licensed physician.